Abacavir/lamivudine/zidovudine ( INNs, trade name Trizivir) is a pharmaceutical treatment for HIV infection. It is a [1 ] fixed dose combination of three reverse transcriptase inhibitors patented by GlaxoSmithKline and now marketed by its joint venture with Pfizer, ViiV Healthcare: [2 ]
It is indicated in the treatment of
AIDS/HIV. For this purpose, the combination is very useful in [3 ] pregnant women to decrease the risk of mother-to-child transmission. [4 ]
The combination of drugs helps to reduce HIV's resistance (through mutation) to the drugs individually. Of the three, AZT and ABC have passed out of United States
In December 2013,
Lupin Limited launched a generic version of Trizivir. [5 ] [6 ]
See Also [ edit ]
References [ edit ]
^ Opravil, Milos; Hirschel, Bernard; Lazzarin, Adriano; Furrer, Hansjakob; Chave, Jean‐Philippe; Yerly, Sabine; Bisset, Leslie R.; Fischer, Marek; Vernazza, Pietro; Bernasconi, Enos; Battegay, Manuel; Ledergerber, Bruno; Günthard, Huldrych; Howe, Colin; Weber, Rainer; Perrin, Luc (May 2002). "A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection". The Journal of Infectious Diseases 185 (9): 1251–1260. doi: 10.1086/340312.
^ InPharm.com: GlaxoSmithKline-Pfizer launch HIV joint venture
^ Drugs.com: Trizivir
^ Horvath, Tara; Madi, Banyana C; Iuppa, Irene M; Kennedy, Gail E; Rutherford, George W; Read, Jennifer S.; Horvath, Tara (2009). "Interventions for preventing late postnatal mother-to-child transmission of HIV" (1). pp. CD006734. doi: 10.1002/14651858.CD006734.pub2. PMID 19160297.
^ Monthly Prescribing Reference (MPR): 
^ Lupin Pharma: